STOCK TITAN
  1. Home
  2. News
  3. ACET

Adicet Bio Inc - ACET STOCK NEWS

Welcome to our dedicated news page for Adicet Bio (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adicet Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adicet Bio's position in the market.

News
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Rhea-AI Summary
Adicet Bio presented preclinical data on ADI-270, showing robust anti-tumor activity and enhanced functional potency in CD70-positive cancers. They are on track to file an IND application for ADI-270 in 2Q 2024. The data will be featured in an oral presentation at ASGCT's 27th Annual Meeting on May 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
clinical trial
-
News
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Rhea-AI Summary
Adicet Bio, Inc. (ACET) announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference where the President and CEO will join a panel discussion on 'Off-the-Shelf CART - Let's Talk Lupus and Oncology'. The event is scheduled for April 15, 2024, at 3:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
-
News
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Adicet Bio, Inc. granted an inducement award on March 28, 2024, to a new employee, providing non-qualified stock options to purchase 99,400 shares at $2.35 per share. The vesting schedule spans four years, with gradual vesting over monthly installments. The award was granted outside of the equity incentive plans under the 2022 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
News
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) expanded its clinical pipeline into autoimmune diseases with FDA clearance for ADI-001, initiating a Phase 1 trial in lupus nephritis in 2Q 2024. The company plans to file IND for ADI-270 in renal cell carcinoma. Adicet extended its cash runway into 2H 2026, positioning itself well for future milestones and clinical execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
earnings
-
News
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced Chen Schor, President and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. The event will focus on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
News
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Adicet Bio, Inc. (ACET) granted an inducement award to a new hire on February 29, 2024, consisting of 7,000 non-qualified stock options at an exercise price of $2.35 per share. The options will vest over a four-year period, subject to continued employment. The award was issued under Adicet's Inducement Plan outside of the regular equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
News
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced that Chen Schor, President and CEO, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will feature a live audio webcast accessible on the company's website. Adicet Bio is a clinical stage biotechnology company focusing on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
-
News
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award to a new employee, consisting of 7,000 non-qualified stock options with an exercise price of $2.99 per share. The options will vest over a four-year period, subject to the employee's continued employment. The award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to the 2022 Inducement Plan, authorized by the compensation committee of the board of directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
none
-
News
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced the closing of its underwritten public offering, raising approximately $98.0 million. The offering included 32,379,667 shares of common stock and pre-funded warrants to purchase 8,445,333 shares. Jefferies, Guggenheim Securities, and Truist Securities were involved in the offering. The securities were offered pursuant to a shelf registration statement filed with the SEC on May 9, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
News
Adicet Bio, Inc. Announces Pricing of Public Offering
Rhea-AI Summary
Adicet Bio, Inc. has announced a public offering of common stock and pre-funded warrants, with an expected gross proceeds of approximately $85.2 million. The offering aims to raise funds for the clinical stage biotechnology company's research and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
offering
Stock ACET logo
Adicet Bio Inc

Nasdaq:ACET

ACET Rankings

#3955 Ranked by Market Cap
#5484 Ranked by Stock Gains
N/A Ranked by Dividends

ACET Stock Data

179.92M
49.05M
1.42%
67.94%
9.36%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Boston

About ACET

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v